1
2
3
4
5
6
7 LONG TITLE
8 General Description:
9 This bill addresses sickle cell disease among residents of the state.
10 Highlighted Provisions:
11 This bill:
12 ▸ requires the Division of Population Health (division) in collaboration with others
13 within the Department of Health and Human Services to review and develop
14 recommendations for improving the surveillance, screening, diagnosis, and
15 treatment of sickle cell disease among residents of the state;
16 ▸ requires the division to report the recommendations to the Health and Human
17 Services Interim Committee;
18 ▸ establishes a repeal date; and
19 ▸ makes technical changes.
20 Money Appropriated in this Bill:
21 None
22 Other Special Clauses:
23 None
24 Utah Code Sections Affected:
25 AMENDS:
26 63I-2-226, as last amended by Laws of Utah 2022, Chapters 255, 365
27 ENACTS:
28 26B-7-120, Utah Code Annotated 1953
29
30 Be it enacted by the Legislature of the state of Utah:
31 Section 1. Section 26B-7-120 is enacted to read:
32 26B-7-120. Sickle cell disease.
33 In collaboration with the Medicaid program as defined in Section 26B-3-101, the Drug
34 Utilization Review Board created in Section 26B-3-302, the Health Data Committee created in
35 Section 26B-1-413, the Office of Health Disparities Reduction created in Section 26B-7-114,
36 and others within the department, the Division of Population Health created in Section
37 26B-1-204 shall:
38 (1) review and develop recommendations for improving the surveillance, screening,
39 diagnosis, and treatment of sickle cell disease among residents of the state; and
40 (2) report the recommendations to the Health and Human Services Interim Committee
41 before July 1, 2024.
42 Section 2. Section 63I-2-226 is amended to read:
43 63I-2-226. Repeal dates: Titles 26 through 26B.
44 [
45
46 [
47 [
48 [
49 [
50 [
51 26-8a-602(1)(a) is amended to read:
52 "(a) provide the patient or the patient's representative with the following information
53 before contacting an air medical transport provider:
54 (i) which health insurers in the state the air medical transport provider contracts with;
55 (ii) if sufficient data is available, the average charge for air medical transport services
56 for a patient who is uninsured or out of network; and
57 (iii) whether the air medical transport provider balance bills a patient for any charge not
58 paid by the patient's health insurer; and".
59 [
60 [
61
62 [
63 fertilization and genetic testing, is repealed July 1, 2030.
64 [
65 26-21-32(1)(a) is amended to read:
66 "(a) provide the patient or the patient's representative with the following information
67 before contacting an air medical transport provider:
68 (i) which health insurers in the state the air medical transport provider contracts with;
69 (ii) if sufficient data is available, the average charge for air medical transport services
70 for a patient who is uninsured or out of network; and
71 (iii) whether the air medical transport provider balance bills a patient for any charge not
72 paid by the patient's health insurer; and".
73 [
74 [
75 Program, is repealed July 1, 2027.
76 [
77 [
78 [
79 repealed July 1, 2024.
80 (9) Section 26B-7-120, relating to sickle cell disease, is repealed July 1, 2025.